Credit: Getty Images Nonmodifiable risk factors for DLB include age and family history. Risk increases substantially in individuals with a first-degree relative who has DLB, including a 2-fold ...
New neflamapimod capsules led to slower DLB progression and greater plasma biomarker improvements over 32 weeks. GFAP levels dropped by 21.2 pg/mL in low ptau181 patients, with fewer falls seen versus ...
Cognition Therapeutics Inc. (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders including Dementia with Lewy Bodies (DLB), just received assistance in those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback